KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd
's (MGRC) wholly-owned subsidiary MGRC Healthcare Sdn Bhd is collaborating with De Cell Bhd for the commercialisation of the former's cell-gene therapy programme.
In a statement, the genomics and biopharmaceutical specialist said it will provide technical and production support to optimise the operational efficiency and market deployment of the EXOGENETIX programme.
De Cell will take on the role of exclusive marketing partner, overseeing all promotional and trademark activities to amplify the programme's market presence and success.
"This collaboration underscores MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies.
"By combining MGRC Healthcare's production capabilities with De Cell's marketing acumen, this partnership is poised to significantly advance the reach and effectiveness of the EXOGENETIX programme," said Malaysian Genomics executive chairman Azri Azerai.
